Clinical Trials Database

Specialty/ Disorder

Study  Information

Purpose

PI Name
/Sponsor

More Information

Contact

Depression

This study is currently recruiting participants.


Population:
Adults age 18 to 40 

Setting:
Outpatient

Duration: 14 months

This is a multi-site, randomized, open-label, effectiveness trial comparing three treatment arms for Major Depressive Disorder patients with Treatment Resistant Depression who are currently on ongoing, stable and adequate antidepressant therapy (ADT). Patients will be randomized in a 1:1:1 fashion to one of three treatment arms: a) aripiprazole augmentation, b) rTMS augmentation, and c) switching to venlafaxine XR or duloxetine.

Primary Aim 1:  To compare the effectiveness of augmentation of antidepressants with aripiprazole versus switching to venlafaxine XR or duloxetine in MDD patients with TRD.

Primary Aim 2: To compare the effectiveness of augmentation of antidepressants with rTMS versus switching to venlafaxine XR or duloxetine in MDD patients with TRD.

Scott Aaronson, MD

Sheppard Pratt Health System

Click here to visit clinicaltrials.gov for more information.

Jennifer Sklar or call 410-938-3136

Schizophrenia

This study is currently recruiting participants.

Population:
Adults age 18 to 40 

Setting:
Outpatient

This study is seeking volunteers for a clinical trial that may improve cognitive functioning. 

Participants take add-on valacyclovir or placebo for sixteen weeks and are compensated for their time. 

Eligibility:

  • 18 - 40 years old

  • Diagnosed with Schizophrenia or Schizoaffective Disorder within the past eight years

Faith Dickerson, PhD, MPH 

Sheppard Pratt Health System Towson, MD

(Coordinating site: Indiana University)

Click here to visit clinicaltrials.gov for more information

Cassie Stallings, R.N. or call 410-938-4356 

Schizophrenia

This study is currently recruiting participants.

Population:
Adults age 18 to 68

Setting:
Outpatient 

This study is seeking volunteers who experience unusual thinking or delusions for a clinical trial to improve symptoms. Participants take add-on d-cycloserine or placebo while receiving twelve weeks of cognitive behavior therapy and are compensated for their time.

Eligibility:

  • 18 - 68 years old

  • Diagnosed with Schizophrenia or Schizoaffective Disorder 

Faith Dickerson, PhD, MPH

Sheppard Pratt Health System Towson, MD

(Coordinating site: New York University School of Medicine)

Click here to visit clinicaltrials.gov for more information

Cassie Stallings, R.N. or call 410-938-4356

Major Depressive Disorder

This study is currently recruiting participants.

Population: Adults age 22 to 65

Setting: Outpatient

This is a double-blind, sham controlled, multi-center study to confirm the safety and efficacy of synchronized transcranial magnetic stimulation (sTMS) for the treatment of patients currently experiencing an episode of depression who have failed to respond to at least one (1) antidepressant medication. Patients will be randomly assigned to either active or sham therapy and will undergo daily treatments for a period of time. Following completion of blinded treatments, patients may be eligible for a course of open label treatments.

Scott Aaronson, MD

Sheppard Pratt Health System

Click here to visit clinicaltrials.gov for more information

Marylu Ortiz or call 410-938-3135

Bipolar Disorder

This study is currently recruiting participants.

Population: Adults age 18+

Setting: Outpatient

This study is an Open-Label study of Transcranial Magnetic Stimulation (TMS) in patients with Bipolar Disorder who are currently depressed.

Scott Aaronson, MD

Sheppard Pratt Health System

Click here to visit clinicaltrials.gov for more information

Jennifer Sklar or call 410-938-3136

If you are interested in participating in one of the above studies, please email or call the contact listed next to the studies we are actively recruiting for or complete the adjacent form to submit your contact information.

Interested in a Clinical Trial?

Select the study in which you are interested below: